Prakash C. Neupane, MBBS

Professional Background

I am a medical oncologist who is focused on head and neck and thoracic oncology. I am also the director of the hematology-oncology fellowship and chair of the head and neck disease working group. The area of research is clinical research in head and neck / thoracic oncology. I have worked in small community as general hematology oncology and with NCI comprehensive cancer center, KU Cancer center since 2008 focused on head and neck and thoracic oncology.
In addition to clinical care, clinical research, I am also interested in graduate medical education. I am the director of fellowship working to expand training in cancer care for future academic physician as well as clinicians for community around Kansas City and rural Kansas. Recent addition of community track in the fellowship program is expected to increase hematology oncology physician in local community.

• MBBS, Medical School, equivalent to US MD , Tribhuvan University, Kathmandu, Nepal
• Residency, Internal Medicine, St. Barnabas Hospital-Affiliated with NY Hospital/Cornell , Bronx, NY
• Clinical Fellowship, Hematology and Medical Oncology, Louisiana State University Health Sciences Center- Shreveport, Shreveport, LA

• Kansas Medical license , Kansas State Board of Healing Arts
• Missouri Board of Healing arts
• Prakash Neupane, American Board of Hematology
• Prakash Neupane, American Board of Medical Oncology

• American Society of Clinical Oncology, ASCO Scientific Program Committee, Member, 2026 - 2029
• American Society of Clinical Oncology, ITE Task Force , Member, 2019 - 2022
• American Society of Clinical Oncology, ASCO, Member, 1998 - Present

---

Research

Overview

I am actively working as head and neck cancer disease working group chair. Several clinical trials are open in the head and neck cancer area including new innovative cell therapy, immune therapy other new novel drugs trials in head and neck cancers. I am interested to work on innovative trials immune altering clinical research. I am open to any collaboration with any translational researcher and industry for such innovative clinical research.

• Mohyuddin Ghulam Rehman, Dominick Anthony, Black Travis Jonathan, Hoffman Marc, Male Heather, Byrd Kenneth, McClune Brian, Eck Leigh, Neupane Prakash C. 2020. A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency. Journal of Cancer Education. https://rdcu.be/b4mps
• Huang Chao H, Wick Jo, Sittampalam Gurusingham Sitta, Victor Sanjit Nirmalanandhan Victor Sanjit, Ganti Apar Kishor, Neupaane Prakash C, Williamson Stephen K, Godwin Andrew K, Schmitt Sarah, Smart Nora J, Spencer Sarah, Van Veldhuizen Peter J. 2014. A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer. FRONTIERS IN ONCOLOGY, 14 (4), 271
• Burke Ellen, Rockey Michelle, Grauer Dennis, Henry Dave, Neupane Prakash Chandra. 2017. Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center. MEDICAL ONCOLOGY, 34 (4)
• Lominska Chris, Estes Christopher Fleighton, Neupane Prakash, Shnayder Yelizaveta, Tennapel Mindi, O’Neil Maura F. 2017. CASTLE thyroid tumor: A case report and literature review. Frontiers in Oncology, 7, 207
• Adkins D, Ley J, Neupane Prakash, Worden F, Sacco AG, Palka K, Grilley-Olson JE, Maggiore R, Salama NN, Trinkaus K, Van Tine BA, Steuer CE, Saba NF, Oppelt P. 2019. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.. The Lancet Oncololgy, 20 (9), 1295
• Ferris Robert L, Saba Nabil F, Gitlitz Barbara J, Haddad Robert, Sukari Ammar, Neupane Prakash, Morris John C, Misiukiewicz Krzysztof, Bauman Julie E, Fenton Moon, Jimeno Antonio, Adkins Douglas R, Schneider Charles J, Sacco Assuntina G, Shirai Keisuke, Bowles Daniel W, Gibson Michael, Nwizu Tobenna, Gottardo Raphael, Manjarrez Kristi L, Dietsch Gregory N, Bryan James Kyle, Hershberg Robert M, Cohen, Ezra E. W.. 2018. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial. JAMA Oncology, 4 (11), 1583-1588
• Dulal Soniya, Paudel Bishnu D, Neupane Prakash, Shah Arati, Acharya Bibek, Paudel Bishesh S, Silpakar Ramila, Wood Lori. 2019. Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting. Journal of Global Oncology (5), 1-6
• Narveson Lisa, Kathol Emily, Rockey Michelle, Henry David, Grauer Dennis, Neupane Prakash Chandra. 2016. Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. MEDICAL ONCOLOGY, 33 (10)
• Dakhil Christopher, Wick Jo, Loknath Kumar Anup Kasi, Satyan Megha Teeka, Neupane Prakash Chandra. 2014. Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature. MEDICAL ONCOLOGY, 31 (10), 187
• Burtness Barbara, Rischin Danny, Greil Richard, Soulieres Denis, Tahara Makoto, de Castro, Gilberto, Psyrri Amanda, Baste Neus, Neupane Prakash, Bratland Ase, Fuereder Thorsten, Hughes Brett G, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Ishak, Wan Zamaniah Wan, Ge Joy, Swaby Ramona, Gumuscu Burak, Harrington Kevin. 2020. Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score < 1, 1-19, and >= 20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis. CANCER RESEARCH, 80 (16)